One example for anti-CD19 CARs in B cell lymphoma treatment is Hu19-CD828Z (NCT02659943), which was assessed in a small clinical trial already and led to lower neurotoxicity compared to the clinically applied axicabtagene ciloleucel [75]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.